A retrospective study to assess cost-effectiveness and safety of palbociclib and everolimus for treating advanced and recurrent breast cancer
Latest Information Update: 07 Oct 2020
At a glance
- Drugs Everolimus (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 07 Oct 2020 New trial record